TB-500: A Fragment Borrowing a Larger Molecule's Record

The short version

TB-500 is a small synthetic peptide — seven amino acids, sequence Ac-LKKTETQ — corresponding to the actin-binding region of a larger natural protein, thymosin beta-4 (Tβ4). Actin is part of the internal skeleton cells use to maintain their shape and to migrate toward a wound; by regulating actin dynamics, the parent protein is closely tied to cell movement, healing, and new blood-vessel growth ^[11].

The single most important distinction about TB-500: in the store and in anti-doping labs, "TB-500" refers to the seven-amino-acid fragment. But most published efficacy research was conducted with full-length thymosin beta-4, which is roughly five times larger ^[1]. It is not established that the small fragment reproduces what the whole protein does at the doses used in peptide research. TB-500 is not an approved medicine; it is banned in sport; and this page reports doses only as they were studied — never as advice.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide with sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, corresponding to residues 17-23 of thymosin beta-4 (Tβ4; gene TMSB4X), the endogenous 43-amino-acid G-actin-sequestering protein. This LKKTETQ stretch is the conserved actin-binding region of the beta-thymosin family.

The identity distinction matters throughout this page: the fragment sold as "TB-500" weighs approximately 889 daltons; full-length Tβ4 is approximately 4,963 daltons. The X-ray crystallographic structure of the G-actin / Tβ4-derived gelsolin-hybrid complex established that Tβ4 forms a 1:1 complex with G-actin, capping both ends of the monomer and preventing polymerization — the structural basis for its actin-buffering role ^[16]. Where a study below used the full protein rather than the 7-mer, this page flags it.

How it works

Full-length thymosin beta-4 is the body's major intracellular G-actin sequestering peptide. "G-actin" is the free, single-unit form of actin; "sequestering" means Tβ4 binds and holds those units in an unpolymerized pool, available for rapid assembly when a cell needs to crawl, divide, or reshape. Crystal-structure work confirmed the 1:1 G-actin capping mechanism at 2-angstrom resolution ^[16].

By regulating the actin skeleton, Tβ4 (and the LKKTETQ motif it contains) is associated with faster cell migration, new blood-vessel growth, anti-inflammatory signaling, reduced apoptosis, decreased scar-forming myofibroblast activity, and recruitment of progenitor cells — a consolidated mechanism described across dermal-wound, corneal, heart and CNS models ^[11]. Whether the isolated seven-amino-acid TB-500 fragment reproduces all of that at the doses used in peptide research has not been shown in controlled human trials ^[1][11].

What the research shows

Regulatory and safety framing. A 2026 Sports Medicine narrative review covering TB-500/thymosin beta-4 and BPC-157 among unapproved musculoskeletal peptides concluded that unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight ^[1].

Consolidated mechanism. A multi-model review consolidated thymosin beta-4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development in dermal wounds, corneal injury, heart and CNS repair ^[11]. Note: this review addresses full-length Tβ4.

Structural basis. X-ray crystallography of a gelsolin-domain-1-Tβ4 hybrid bound to actin established that Tβ4 forms a 1:1 complex with G-actin, sequesters the monomer by capping both ends, and prevents polymerization; the WH2 actin-interacting motif underlies this ^[16].

Human safety (full-length protein, not the fragment). In a randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 was given intravenously to 40 healthy volunteers — single dose then daily for 14 days at 42, 140, 420 or 1260 mg. Well tolerated; only infrequent mild-to-moderate adverse events; no dose-limiting toxicities; no serious adverse events; dose-proportional pharmacokinetics ^[15]. This data is for full-length Tβ4, not the TB-500 fragment.

Animal dose-response (full-length protein). In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 h post-stroke, then every 3 days for 4 more doses) improved neurological function significantly from day 14 through day 56; 18 mg/kg gave no significant benefit — a non-monotonic result where more was not better ^[14].

Reported effects, cautions & safety

No community-anecdote signals are compiled in this desk's source material for TB-500 as a standalone. The following cautions come from the cited literature.

• Identity confusion. Most efficacy claims for TB-500 rest on full-length thymosin beta-4 data. It is not established that the Ac-LKKTETQ fragment reproduces the parent protein's effects; efficacy claims for the fragment in humans are unproven ^[1].
• Tumor / angiogenesis signal. Thymosin beta-4 is overexpressed in several cancers (e.g., pancreatic, colorectal) and implicated in metastasis and tumor angiogenesis. The same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[11].
• Non-monotonic dosing. In the rat stroke dose-response study, 2 and 12 mg/kg improved outcomes but 18 mg/kg did not — higher is not necessarily better, undermining community loading rationales ^[14].
• No human trials for the fragment. No completed controlled clinical trials of the TB-500 heptapeptide fragment exist for any indication ^[1].
• WADA prohibition. TB-500 (and thymosin beta-4) are prohibited by WADA under peptide/growth-factor categories; banned in and out of competition. TB-500 has been detected as a doping agent in racehorses, prompting dedicated LC-MS anti-doping assays ^[1].
• Unregulated supply. TB-500 is not an approved drug; product identity, purity and correct sequence (full-length vs fragment) are not guaranteed in unregulated supply.

Where it fits in recovery research

TB-500 occupies a particular position on this desk: a compound whose mechanism — actin regulation driving cell migration — is well described at the full-protein level, but whose evidence as the actual sold fragment is the thinnest of the four ^[1]. It is a component of both Wolverine and KLOW. Where BPC-157 leads with angiogenesis, TB-500's story is largely thymosin beta-4's story, borrowed — making it the clearest case study in why this field rewards reading the primary citations rather than the marketing. See the comparison page for how all four line up.